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This paper addresses two critical issues concerning the guidelines adopted by the ICH on the photo-
stability testing: the quinine actinometry method and the light/radiation exposure map distribution of
the photostability chamber. Using a qualiﬁed non-commercial photostability chamber tests were per-ccepted 10 November 2010
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formed using quinine and physical actinometry and compared the results to those which are used as the
basis of the ICH guidelines. The statistical analysis on the results showed that: (i) the calibration curve
of the quinine solution depends on its concentration and on its location in the chamber; (ii) the quinine
actinometry method currently recommended by the ICH guidelines should not be generalized to any
photostability chamber.uinine actinometry
xposure surface
. Introduction
Photostability testing is typically performed under controlled
onditions, often in a chamber where exact exposure levels of the
ight spectrum are delivered for precise analysis of the effects. To
erform photostability testing it is necessary to know the spectral
nd intensity distribution of the radiation source to ensure that a
recise amount of radiation is homogeneously distributed on the
urface area where the product will be exposed [1–5]. Thereby, it
s necessary to guarantee a thorough and secure qualiﬁcation of
he photostability chamber in order to prove that this equipment
s suitable to photostability testing [6]. There are two experimen-
al ways to qualify the photostability chamber and to determine
he correct applied radiation dose: (i) by using chemical actinom-
try and (ii) by applying a physical device (physical actinometry
r radiometry) on which the (radiation) number of photons in a
eﬁned space can be fully determined [6–8].
Quinine actinometry is an adopted standard method for cali-
rating the intensity of UV radiation (300–400nm) of the radiation
ight sources used in photostability testing. This methodology is
eported in the U.S. Food and Drug Administration (FDA)/National
nstitute of Standard and Technology (NIST) studies and is the basis
or different ofﬁcial parameters that guide the stability testing of
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pharmaceuticals [1–3,6]. The known paper of Yoshioka et al. [9]
proposed quinine actinometry as a universal standardized method
for calibratingUV intensity in light sources [9]. Thispaperpresented
a joint study of seven different laboratories and showed that there
is a linear correlation between the quinine absorbance and the inte-
grated UV radiation. The referred study was performed using a 5%
quinine solution which was exposed to different UV sources and
the authors suggested that being this solution too concentrated it
would be more interesting to use a 2.5% quinine solution instead.
The slope of both regression curves was compared and considered
similar so that they could be used indistinctively, however these
resultswerenot comparedstatisticallyby theauthors. These results
were later used as the basis of the Q1B photostability testing guide-
lines described by the International Conference on Harmonization
of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) [1]. Although the main topics are addressed by
these guidelines, there is still a great deal of fundamental ques-
tions concerning the photostability testing that remain unclear.
Different authors have pointed out some of these questions in the
literature since the publication of the ICH guidelines [10,11]. An
example is the quinine chemical actinometry. Not only thismethod
is poorly described in the guide but also it was shown by Baertschi
et al. that its reproducibility depends on the experimental condi-
Open access under the Elsevier OA license.tions (measurement time interval, pH, temperature, oxygenation,
lamp emission spectrum) [10–12]. Themain purpose of the present
study is to show experimentally some divergences that arise when
applying the quinine actinometry using different quinine solution
concentrations.
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The absorbance versus irradiation plots of the 2% and 5% (w/v)
UV exposed quinine solutions are depicted in Fig. 2 and the results
of the angular and linear coefﬁcients of both curves are described
in Table 1, which also presents Yoshiokaıˇs data [9]. Two main con-
siderations may be drawn when applying the statistical analysisC.A. de Azevedo Filho et al. / Journal of Pharma
. Experimental
The present study was performed in a photostability chamber
quipped with one ultraviolet lamp with 22W UV power in accor-
ance to the Guidance for Industry Q1B Photostability Testing of
ew Drug Substances and Products by ICH [1]. The temperature in
he chamber was kept at 28±1 ◦C. A radiometer model MRU-201
InstruthermTM – Brazil) maximum range 200Wh/m2 was used to
etermine theultraviolet irradiance and theaveragevaluewasesti-
atedwith at least 10measurements. Lamp emission spectrawere
ollected on a spectrophotometer model HR4000 (Ocean OpticsTM
Germany) and the absorption spectra were registered in a 10mm
uartz cuvette on a Cary 50 Bio spectrophotometer (Varian Inc. –
SA) and.Quininemonohydrochloride anhydratewith a 90%purity
radewas purchased from Sigma–Aldrich (Germany) andwas used
o prepare. Solvents and other reagents were of the highest purity
ommercially available. Chemical calibration was performed using
uinine monohydrochloride in 2% and 5% (w/v) aqueous solution
ealed in glass vials.
A conﬁdence interval of 95%, with alpha=5% and n−2 degrees
f freedom, has been constructed for the absorption curves of the
% and 5% (m/v) quinine solutions in order to compare with the
esults obtained by Yoshiokaıˇs group [9]. Two different situations
ere evaluated: (1) the agreement of the conﬁdence interval of the
% and5% (m/v) curves obtained byuswith the 5% (m/v) concentra-
ion curve obtained by Yoshioka and (2) the agreement conﬁdence
nterval of the 2% and 5% (m/v) curves in relationship to each other
easured in the same photostability chamber. In the statistical
nalysis we assume that there is an agreement between the results
f both curves only when there is a conﬁdence interval overlap for
he slopes and for the linear coefﬁcient of the curves.
. Results and discussion
.1. UV irradiance intensity and surface exposure mapping
Thephotostability chamberused in thepresent study is in accor-
ance to the ICH (option 2) guideline [1]. The emission spectrum
nd the band proﬁle of the UV lamp agree with the manufacturerıˇs
escription and also to the ICH recommendations, having a spectral
istribution from 320 to 400nm and maximum at 362nm. Theo-
etical estimative of the direct incidence of UV radiation (based on
ata of the UV power emission supplied by the manufacturer) was
alculated by dividing the UV power output by the total sample
xposure area. The estimated irradiance is I=12.3W/m2.
Although there is no ofﬁcial recommendation on the location
f the sample in the chamber some authors have reported a high
ariability of radiation and light dose depending on the type of the
hotostability chamber used and on the positioning of the sample
nside the chamber [2,3,6]. Taking this information into account we
erformed the surface exposure mapping in order to characterize
his parameter. This procedure is necessary to ensure a homoge-
eous irradiance distribution to the analyzed sample, and in the
resent study, to ensure the repeatability of the quinine actinom-
try system. The chamber irradiation intensity mapping in the UV
egion (measured in W/m2) is shown in Fig. 1. We observe a non-
niform distribution in the intensity of UV radiation on the sample
xposure area and this is probably related to the location of the
amp in the chamber. This central region presents an irradiation
ntensity which corresponds to an irradiance of I=14.45W/m2,
howing a good agreement with the theoretical estimative.
Observing the UV irradiation mapping we observe that, as
xpected, the further away from the center of the radiation source
he lower the irradiation intensity. It is interesting to observe the
ifference in uniformity of the distribution of UV radiation, evenFig. 1. UVA irradiation intensity mapping (Wh/m2) of the photostability chamber.
The numbers indicate the irradiance percentages.
with the chamber walls covered with aluminum sheets to provide
better light distribution. This distribution proﬁle shows that only
a restricted area may be used to induce a uniform photodegrada-
tion kinetics of the sample. As each photostability chamber has its
own design one has to estimate the working area which will guar-
antee a homogeneous radiation output to the drug, thus, providing
reproducible degradation kinetics. In Fig. 1, we observe an ellip-
soidal gradient graph shape for the lamp used and the difference
in intensity average between the central region (I=14.45W/m2)
and peripheral region (I=6.2W/m2) is approximately 55%. Never-
theless, the central value of the gradient shape graph is close to the
theoretical value calculated consideringonly thedirect incidenceof
light. This suggests that the UV radiation is practically not reﬂected
by the surface inside the chamber, i.e., the degradation due to UV
radiation is resulting by direct incidence. This inhomogeneous sur-
face mapping, also observed by other authors, corroborates that
to ensure the reproducibility of the photostability testing and to
guarantee a reliable comparison among different chambers, a sur-
face exposure mapping should always be performed. We strongly
suggest that the ICH review the Guideline Q1B to include this rec-
ommendation.
3.2. Quinine actinometry methodFig. 2. Absorption at 400nm versus energy density (E) calibration curve of UV
degraded quinine solutions. (L1) 5% quinine solution reported by Yoshioka et al.
[9]; (L2) 2% and (L3) 5% quinine solutions. The insert shows the projection of the
calibration curves of the UV degraded quinine solutions.
888 C.A. de Azevedo Filho et al. / Journal of Pharmaceutical and Biomedical Analysis 54 (2011) 886–888
Table 1
Results of the calibrating curve coefﬁcients obtained in this work and by Yoshioka et al. [9].
Slope (Wh/m2) Intercept Adjusted R2
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[Quinine solution 2% (w/v) 0.00451±7.2×10−5
Quinine solution 5% (w/v) 0.00411±6×10−5
Yoshioka et al. 0.00381±47×10−5
escribed in the present study. First, the agreement of the conﬁ-
ence interval of the2%and5% (m/v) curves obtainedbyuswith the
% (w/v) concentration curve obtained by Yoshioka et al. [9] is not
tatistically comparable with 95% of conﬁdence. This implies that
oshiokaıˇs results should not be generalized to any UV lamp. The
urve shown in Yoshiokaıˇs work (and plotted in Fig. 2) corresponds
o an average angular coefﬁcient obtained from seven slopes esti-
ated for seven different lamps and cannot be generalizedwithout
mplying large errors. Second, the agreement of the conﬁdence
nterval of the 2% and 5% (w/v) curves in relationship to each other
nd measured in the same photostability chamber indicates that
hequinine actinometry is concentrationdependent. As canbe seen
n Table 1, there is no overlap at 95% conﬁdence intervals of the 2%
nd 5% (w/v) quinine curves, so, it is not possible to say that these
urves are statistically comparable. Analyzing Fig. 2 we see that the
urves meet at one single point (at I=194.13Wh/m2) and differ-
nces between the curves are more evident under 150Wh/m2 and
bove 200Wh/m2. This dependence with the concentration has a
irect impact on the ICH guideline. Yoshiokaıˇs work uses quinine
olutions at 5% (w/v) while the ICH and FDA recommends the use
f 2% (w/v) quinine solutions as a reference for conducting drug
hotostability studies. Although this value may be considered neg-
igible for somesubstances itmayalso result in agreatdifference for
ighlyphotosensitive compounds. Thesewill showgreat decompo-
ition rates even at smaller radiation doses and may be completely
egraded in very short time periods, requiring a reduced exposure
ime to fully monitor its photodegradation kinetics.
The present considerations add to the results and comments
eported by Baertschi et al. which demonstrated strong evidences
hat a more thorough study should be performed on the quinine
ystem [10,11]. We also agree that the quinine actinometry system
snot yet completely validated to be applied as the idealmethod for
hotostability testing and the ICH guidelines should be reviewed
o include more detailed and reliable experimental conditions to
nsure the reproducibility of this actinometry system.
. ConclusionsWeperformed tests using quinine andphysical actinometry and
ompared the results to those which are used as the basis of the
CH guidelines. The results point out that the calibration curve of
he quinine solution depends on its concentration and on its loca-
ion in the chamber and we suggest that the quinine actinometry
[0.03868 ± 0.00285 0.992
0.11633 ± 0.002368 0.993
0.145 ± 0.009
method currently recommended by the ICH guidelines should not
be generalized to any photostability chamber. Moreover we sug-
gest that to ensure the reproducibility of the photostability testing
and to guarantee a reliable comparison between different cham-
bers, a surface exposure mapping should always be performed and
this measurement should be recommended by the ICH guidelines.
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